By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTPipeline UpdateEarlier this week Durect (NASDAQ:DRRX) provided a corporate and pipeline update. Much of the focus was, as expected, on DUR-928. Particularly noteworthy is that the company announced a somewhat updated strategy as it relates to DUR-928 - specifically that they...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateTreatment with Exebacase Beneficial to S. Aureus Bacteremia PatientsOn January 7, 2019, ContraFect Corp. (NASDAQ:CFRX) announced topline results from the Phase 2 trial of exebacase (CF-301) in patients with bacteremia caused by Staphylococcus aureus, including those with endocarditis. This was...
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateSet to Initiate Phase 2 Trial in Progressive MSOn December 17, 2018, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for testing NurOwn® in patients...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTOn December 28, 2018, Chicken Soup for the Soul Entertainment (NASDAQ:CSSE) purchased the remaining portion of A+ it did not own from the three remaining A+ shareholders. This was comprised of Class A stock in CSSE as follows: (a) 322,275 shares of...
By John Vandermosten, CFAOTC:GOVXWe visited with GeoVax (OTC:GOVX) management at their facilities in Smyrna, Georgia to review their key programs and identify the expected path forward for the company. Over the last few years, GeoVax has expanded from a single program developing an HIV vaccine to a platform company...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORT12-Month SUI Data, FDA OKs VIVEVE 2 To Progress, LIBERATE U.S. Start-Date Pushed BackIt has been a busy few weeks for Viveve (NASDAQ:VIVE). In addition to raising nearly $19M (net) via the sale of common shares, they recently announced compelling 12-month...
By Lisa ThompsonNYSE:INUVREAD THE FULL INUV RESEARCH REPORTThe S-4 was filed for Inuvo’s (NYSE:INUV) merger with ConversionPoint and we now have some financial and product information on privately held ConversionPoint.ConversionPoint was founded in 2016 in Newport Beach, CA and currently has 96 employees. It purchased two companies in 2017:...
By Lisa ThompsonNASDAQ:CIDMREAD THE FULL CIDM RESEARCH REPORTCinedigm (NASDAQ:CIDM) announced plans to sell 125 digital cinema projection systems from the company’s Phase 1 purchases on or about January 15, 2019 and is currently in the process of selecting an advisory firm with expertise in this area to monetize the...
By Brian Marckx, CFANASDAQ:DAREREAD THE FULL DARE RESEARCH REPORTDARE Acquires Late-Stage Bacterial Vaginosis CandidateDare Bioscience (NASDAQ:DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Their latest addition was announced earlier this month when...
By David Bautz, PhDNASDAQ:ORMPREAD THE FULL ORMP RESEARCH REPORTFinancial UpdateIn Nov. 2018, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) filed form 10-K with financial results for fiscal year 2018 that ended Aug. 31, 2018. The company reported revenues of $2.449 million, which was very similar to the $2.456 million reported in fiscal...